The city of North Canton, Ohio, currently has 4 active clinical trials seeking participants for Alzheimer's Disease research studies.
A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease
Recruiting
The primary purpose of the study is to evaluate the safety and tolerability of emraclidine administered orally to healthy elderly participants in Part A (multiple ascending doses) and participants with dementia due to Alzheimer's disease (AD) in Part B.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
02/18/2025
Locations: North Canton, Ohio, North Canton, Ohio
Conditions: Healthy Participants, Alzheimer's Disease Dementia
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
Recruiting
The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
Gender:
ALL
Ages:
Between 60 years and 80 years
Trial Updated:
02/10/2025
Locations: Local Institution - 0216, North Canton, Ohio
Conditions: Alzheimer Disease, Early Onset
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Recruiting
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective. Digital biomarkers and blood-based biomarkers will be tested to determine whether a meaningful relationship exists between biomarkers alone or in combination with tau or amyloid brain pathology identified through PET images.
Gender:
ALL
Ages:
Between 60 years and 90 years
Trial Updated:
02/03/2025
Locations: Neuro-Behavioral Clinical Research Inc., North Canton, Ohio
Conditions: Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss, Memory Disorders, Memory Impairment
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
Recruiting
The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment \[MCI\] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
12/04/2024
Locations: GSK Investigational Site, North Canton, Ohio
Conditions: Alzheimer's Disease